A Novel Nanoparticle Platelet Analogue for Radiation-Induced Thrombocytopenia

点击翻译按钮获取中文摘要

The contract will advance the development of lead candidate drugs or biological products that increase survival primarily by mitigating and/or treating radiation-induced thrombocytopenia, conduct translational research and development, and provide additional information and data that support submission of an Investigational New Drug (IND) application and eventual FDA approval or licensure. The contract has a well-defined product development path for a lead medical countermeasure that includes IND-enabling studies to be performed under the contract.